196 related articles for article (PubMed ID: 23999921)
1. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
[TBL] [Abstract][Full Text] [Related]
2. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
[TBL] [Abstract][Full Text] [Related]
3. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
[TBL] [Abstract][Full Text] [Related]
4. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
Miyajima T; Onozawa M; Yoshida S; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Goto H; Sugita J; Fujisawa S; Hidaka D; Ogasawara R; Mori A; Matsuoka S; Shigematsu A; Wakasa K; Kasahara I; Saga T; Hashiguchi J; Takeda Y; Ibata M; Yutaka T; Fujimoto K; Kondo T; Teshima T
Eur J Haematol; 2023 Oct; 111(4):620-627. PubMed ID: 37465857
[TBL] [Abstract][Full Text] [Related]
6. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
[TBL] [Abstract][Full Text] [Related]
7. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
Thanasopoulou A; Tzankov A; Schwaller J
Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
[TBL] [Abstract][Full Text] [Related]
8. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
9. [Molecular Characteristics and Clinical Features of Adults with
Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313
[TBL] [Abstract][Full Text] [Related]
10. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
11. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
12. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
13. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinksi JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
17. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.
Wen X; Wu Y; Huang P; Zheng H
Pediatr Blood Cancer; 2023 Jul; 70(7):e30308. PubMed ID: 36965174
[No Abstract] [Full Text] [Related]
20. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.
Jaju RJ; Fidler C; Haas OA; Strickson AJ; Watkins F; Clark K; Cross NC; Cheng JF; Aplan PD; Kearney L; Boultwood J; Wainscoat JS
Blood; 2001 Aug; 98(4):1264-7. PubMed ID: 11493482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
